The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis

Rheumatology (Oxford). 2015 Sep;54(9):1744-5. doi: 10.1093/rheumatology/kev210. Epub 2015 Jun 27.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD20 / genetics*
  • Antigens, CD20 / metabolism*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / pathology
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Biomarkers / metabolism
  • Biopsy
  • Case-Control Studies
  • Drug Resistance / immunology*
  • Female
  • Follow-Up Studies
  • Genetic Variation / genetics*
  • Humans
  • Male
  • Middle Aged
  • Rituximab / therapeutic use*
  • Synovial Membrane / pathology
  • Treatment Outcome

Substances

  • Antigens, CD20
  • Antirheumatic Agents
  • Biomarkers
  • Rituximab